E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Squamous cell cancer of head and neck, unresectable, locally advanced, Stage III/IVa or b (UICC, 2002) |
|
E.1.1.1 | Medical condition in easily understood language |
Cancer of head and neck, unresectable, locally advanced, Stage III/IVa or b (UICC, 2002) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10060121 |
E.1.2 | Term | Squamous cell carcinoma of head and neck |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Determination of feasibility, efficacy and safety of cetuximab (CET) combined with cisplatin (CIS) and hyperfractionated, accelerated radiotherapy (HART) as a treatment option with curative intent for patients with locally advanced, unresectable SCCHN. Phase I: defining the maximum tolerated dose (MTD) of a short infusion of cisplatin in the combined-modality treatment with cetuximab Phase II: Efficacy of combined-modality treatment with regards to progression-free survival. The dose of cisplatin in this combined-modality treatment will be determined in the phase I study.
|
|
E.2.2 | Secondary objectives of the trial |
Phase I: Examining the dose limiting toxicities (DLT) of a short infusion of cisplatin in the combined-modality treatment with cetuximab.
Phase II: Feasibility, efficacy and safety of combined-modality treatment with regards to overall survival, progression-free survival and tumor response. Evaluation of toxicity of HART-CIS-CET.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•Patients with histologically confirmed unresectable SCC of the oral cavity (no lip), oropharynx, hypopharynx or larynx (stage III/IVa or b) •Unidimensionally measurable lesion •Signed informed consent •Karnofsky PS ≥ 70% •Age ≥ 18 and ≤ 70 •Curative treatment intent •Negative serum or urine pregnancy test (women of childbearing potential) •Adaequate bone marrow, hepatic and renal function (for further details see section 5 study protocol)
|
|
E.4 | Principal exclusion criteria |
•Unknown primary cancer, nasopharynx cancer or salivary gland cancer •Metastatic disease •Another cancer within 5 years of study entry •Serious concomitant disease or medical condition •Pregnancy or lactation •Women of child-bearing potential with unclear contraception •Previous treatment with chemotherapy, radiotherapy or surgery in head and neck •Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 30 days prior to study screening •Life expectancy < 3 months •Contraindications to receive cisplatin or cetuximab •Previous exposure to monoclonal antibodies and/or EGFR-targeted therapy •Social situations that limit the compliance with study requirements (for further details see section 5 study protocol)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Phase I: Determination of maximum tolerated dose (MTD) of cisplatin in HART-CIS-CET measured as maximum tolerated dose of cisplatin (mg/m2) Phase II: Determination of 2-year progression-free survival (PFS), as measured by the 2-year progression-free survival rate. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Phase I: following each administration and 8 weeks after the last administration. Phase II: 2 years after end of treatment |
|
E.5.2 | Secondary end point(s) |
- Progression-free survival as measured by 1- and 5-year progression-free survival rates - Overall survival (OS) as measured by 1-, 2- and 5-year overall survival rates - Loco-regional progression-free survival (LPFS) as measured by 1-, 2- and 5-year loco-regional progression-free rate - Objective tumor response rate (ORR) (according to RECIST) - Toxicity of HART-CIS-CET (according CTCAE, version 3.0)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- Toxicity: following each administration and 8 weeks after the last administration; off-treatment every 6 months (year 1-2) and every 12 months (year 3-5) up to disease progression - PFS: 1-, 2- and 5-year after start of therapy - ORR: 8 weeks after end of therapy followed by every 6 months (year 1-2), every 12 months (year 3-5) up to disease progression - Loco-regional progression-free survival (LPFS): measured 1-, 2- and 5-year after start of therapy |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 11 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 12 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 7 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 7 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 0 |